Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir

Tatsuhiko Wada; Kosuke Shimode; Takayuki Hoshiyama; Yoko Takayama; Kunihiro Yamaoka

doi:10.3389/fmed.2020.00241

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir

Front Med (Lausanne). 2020 May 19:7:241. doi: 10.3389/fmed.2020.00241. eCollection 2020.

Authors

Tatsuhiko Wada¹, Kosuke Shimode¹, Takayuki Hoshiyama^{1

2}, Yoko Takayama², Kunihiro Yamaoka¹

Affiliations

¹ Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan.
² Department of Infection Control and Prevention, Kitasato University Hospital, Sagamihara, Japan.

Abstract

Following the first case of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2), in Wuhan, China, in December 2019, it has spread worldwide. An outbreak in Japan occurred on a cruise ship, and this was followed by community-acquired COVID-19. Herein, we report three cases of COVID-19 that presented pneumonia following admission to Kitasato University Hospital. Patients were admitted based on the positive result of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for COVID-19 nucleic acid. All patients were diagnosed as suffering from non-severe COVID-19 pneumonia and were successfully treated with Lopinavir/Ritonavir (LPV/r). LPV/r could be an option for treating non-severe COVID-19 pneumonia in general and even in elderly patients.

Keywords: COVID-19; Lopinavir; Ritonavir; cruise ship; elderly patient; hyponatremia.

Publication types

Case Reports